Danielle Swinne
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Danielle Swinne has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
N. Nolard
Scientific Institute of Public Health, Mycology Section, Brussels, Belgium
5 shared publications- Françoise Symoens
Scientific Institute of Public Health-Louis Pasteur, Mycology Section, Brussels, Belgium
2 shared publications L. Trilles
2 shared publicationsM. Martins-Nishikawa
2 shared publicationsM. Watelle
Scientific Institute of Public Health, Mycology Section, Brussels, Belgium
2 shared publicationsC. Suetens
Epidemiology section, Scientific Institute of Public Health, Brussels, Belgium
1 shared publication
Latest Publications
- 1 March 2005
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 22 (1) , 24-28
Actividad in vitro del voriconazol, fluconazol, itraconazol y anfotericina B contra levaduras no Candida albicans
- 1 March 2005
- Published by Elsevier in Revista Iberoamericana de Micologia
- Vol. 22 (1) , 24-28
Actividad in vitro del voriconazol, fluconazol, itraconazol y anfotericina B contra levaduras no Candida albicans
In vitro activities of voriconazole (UK‐109, 496), fluconazole, itraconazole and amphotericin B against 132 non‐albicans bloodstream yeast isolates (CANARI study)
The aim was to evaluate the in vitro activity of voriconazole compared with those of amphotericin B, itraconazole and fluconazole against 132 bloodstream isolates of Candida non‐albicans and Saccharomyces cerevisiae species. The minimal inhibitory concentrations (MICs) were determined by an adapted National Committee for Clinical Laboratory Standards (NCCLS) M27‐A method using RPMI 1640 as test medium supplemented with 2% glucose. MIC end‐points were determined with a spectrophotometer after incubation for 48 h at 35 °C. Optical density data were used for the calculation of the MIC end‐points. For amphotericin B, the end‐point was defined as the minimal antifungal concentration that exerts 90% inhibition compared with the control well growth. For the azoles, the end‐points were determined at 50% inhibition of growth. Amphotericin B is highly active with 97% of isolates inhibited by ≤1 μg ml−1. Decreased susceptibility or resistance to fluconazole was the rule among C. krusei, which is intrinsically resistant to fluconazole. For C. glabrata isolates, resistance to fluconazole and itraconazole was measured in 13% and 17% of the isolates respectively. Voriconazole was quite active in vitro against all the isolates with a MIC90% of ≤1 μg ml−1 and we conclude that it may be useful in the treatment of non‐albicans bloodstream infections.
In vitro activities of voriconazole (UK‐109, 496), fluconazole, itraconazole and amphotericin B against 132 non‐albicans bloodstream yeast isolates (CANARI study)
The aim was to evaluate the in vitro activity of voriconazole compared with those of amphotericin B, itraconazole and fluconazole against 132 bloodstream isolates of Candida non‐albicans and Saccharomyces cerevisiae species. The minimal inhibitory concentrations (MICs) were determined by an adapted National Committee for Clinical Laboratory Standards (NCCLS) M27‐A method using RPMI 1640 as test medium supplemented with 2% glucose. MIC end‐points were determined with a spectrophotometer after incubation for 48 h at 35 °C. Optical density data were used for the calculation of the MIC end‐points. For amphotericin B, the end‐point was defined as the minimal antifungal concentration that exerts 90% inhibition compared with the control well growth. For the azoles, the end‐points were determined at 50% inhibition of growth. Amphotericin B is highly active with 97% of isolates inhibited by ≤1 μg ml−1. Decreased susceptibility or resistance to fluconazole was the rule among C. krusei, which is intrinsically resistant to fluconazole. For C. glabrata isolates, resistance to fluconazole and itraconazole was measured in 13% and 17% of the isolates respectively. Voriconazole was quite active in vitro against all the isolates with a MIC90% of ≤1 μg ml−1 and we conclude that it may be useful in the treatment of non‐albicans bloodstream infections.
- Open Access
- 1 April 2004
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 132 (6) , 1175-1180
A one-year survey of candidemia in Belgium in 2002
A total of 211 episodes of bloodstream yeast infections in 207 patients, hospitalized in 28 Belgian hospitals participating in a National Surveillance Program, were evaluated. A total of 81% of the patients were more than 50 years of age. Candida albicans was the cause of infections in 55% of patients, 22% were due to C. glabrata and 13% to C. parapsilosis. The most common predisposing factors were antibacterial therapy (42%), residence in an intensive care unit (32·9%) and presence of an intravascular catheter (29·7%). Most patients had more than one predisposing factor. Fluconazole alone or in association with another antifungal agent was the treatment of choice for 89·7% of the cases. In vitro susceptibility testing of the isolates revealed that 99% were susceptible to amphotericin B, 95% to 5-fluorocytosine, 82% to fluconazole and 69% to itraconazole. Resistance to azoles was more common among C. glabrata isolates in the elderly. We conclude that the frequency of C. albicans infection is decreasing in Belgium and this is associated with the emergence of other species, most notably, C. glabrata.
- 1 April 2004
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 132 (6) , 1175-1180
Open AccessA one-year survey of candidemia in Belgium in 2002
A total of 211 episodes of bloodstream yeast infections in 207 patients, hospitalized in 28 Belgian hospitals participating in a National Surveillance Program, were evaluated. A total of 81% of the patients were more than 50 years of age. Candida albicans was the cause of infections in 55% of patients, 22% were due to C. glabrata and 13% to C. parapsilosis. The most common predisposing factors were antibacterial therapy (42%), residence in an intensive care unit (32·9%) and presence of an intravascular catheter (29·7%). Most patients had more than one predisposing factor. Fluconazole alone or in association with another antifungal agent was the treatment of choice for 89·7% of the cases. In vitro susceptibility testing of the isolates revealed that 99% were susceptible to amphotericin B, 95% to 5-fluorocytosine, 82% to fluconazole and 69% to itraconazole. Resistance to azoles was more common among C. glabrata isolates in the elderly. We conclude that the frequency of C. albicans infection is decreasing in Belgium and this is associated with the emergence of other species, most notably, C. glabrata.
- 1 August 2002
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 40 (4) , 443-445
Prevalence of Candida dubliniensis in the BCCM/IHEM Biomedical Fungi/Yeasts Culture Collection (isolates before 1990)
The BCCM/IHEM Biomedical Fungi/Yeasts collection hosts 1200 Candida albicans strains of the Vanbreuseghem mycotheque isolated between 1951 and 1997. From this collection, 469 freeze-dried C. albicans strains, producing chlamydospores, germ tubes and forming green colonies on CHROMagar, all isolated before 1990, were screened to identify the Candida dubliniensis isolates. Screening was performed in different steps using the growth at 45 degrees C, the assimilation of xylose, the intracellular beta-glucosidase activity test and C. dubliniensis-specific polymerase chain reaction (PCR) with primers from ACT1 intron sequence. Five isolates (1%) were identified as C. dubliniensis: one isolate was not documented, the others were of oropharyngeal origin of which two (1987 and 1990) were from proven human immunodeficiency virus patients.
- 1 August 2002
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 40 (4) , 443-445
Prevalence of Candida dubliniensis in the BCCM/IHEM Biomedical Fungi/Yeasts Culture Collection (isolates before 1990)
The BCCM/IHEM Biomedical Fungi/Yeasts collection hosts 1200 Candida albicans strains of the Vanbreuseghem mycotheque isolated between 1951 and 1997. From this collection, 469 freeze-dried C. albicans strains, producing chlamydospores, germ tubes and forming green colonies on CHROMagar, all isolated before 1990, were screened to identify the Candida dubliniensis isolates. Screening was performed in different steps using the growth at 45 degrees C, the assimilation of xylose, the intracellular beta-glucosidase activity test and C. dubliniensis-specific polymerase chain reaction (PCR) with primers from ACT1 intron sequence. Five isolates (1%) were identified as C. dubliniensis: one isolate was not documented, the others were of oropharyngeal origin of which two (1987 and 1990) were from proven human immunodeficiency virus patients.
- Open Access
- 1 January 2002
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 40 (4) , 443-445
Prevalence ofCandida dubliniensisin the BCCM/IHEM Biomedical Fungi/Yeasts Culture Collection (isolates before 1990)
The BCCM/IHEM Biomedical Fungi/Yeasts collection hosts 1200 Candida albicans strains of the Vanbreuseghem mycotheque isolated between 1951 and 1997. From this collection, 469 freeze-dried C. albicans strains, producing chlamydospores, germ tubes and forming green colonies on CHROMagar, all isolated before 1990, were screened to identify the Candida dubliniensis isolates. Screening was performed in different steps using the growth at 45 °C, the assimilation of xylose, the intracellular ß-glucosidase activity test and C. dubliniensis-specific polymerase chain reaction (PCR) with primers from ACT1 intron sequence. Five isolates (1%) were identified as C. dubliniensis: one isolate was not documented, the others were of oropharyngeal origin of which two (1987 and 1990) were from proven human immunodeficiency virus patients.
- 1 January 2002
- Published by Oxford University Press (OUP) in Medical Mycology
- Vol. 40 (4) , 443-445
Open AccessPrevalence ofCandida dubliniensisin the BCCM/IHEM Biomedical Fungi/Yeasts Culture Collection (isolates before 1990)
The BCCM/IHEM Biomedical Fungi/Yeasts collection hosts 1200 Candida albicans strains of the Vanbreuseghem mycotheque isolated between 1951 and 1997. From this collection, 469 freeze-dried C. albicans strains, producing chlamydospores, germ tubes and forming green colonies on CHROMagar, all isolated before 1990, were screened to identify the Candida dubliniensis isolates. Screening was performed in different steps using the growth at 45 °C, the assimilation of xylose, the intracellular ß-glucosidase activity test and C. dubliniensis-specific polymerase chain reaction (PCR) with primers from ACT1 intron sequence. Five isolates (1%) were identified as C. dubliniensis: one isolate was not documented, the others were of oropharyngeal origin of which two (1987 and 1990) were from proven human immunodeficiency virus patients.